Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 439

1.

Preprocedural therapeutic international normalized ratio influence on bleeding complications in atrial fibrillation ablation with continued anticoagulation with warfarin.

Hayashi T, Kumagai K, Naito S, Goto K, Kaseno K, Ohshima S, Hachiya H, Hirao K, Isobe M.

Circ J. 2013;77(2):338-44. Epub 2012 Oct 20.

2.

Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.

Gautam S, John RM, Stevenson WG, Jain R, Epstein LM, Tedrow U, Koplan BA, McClennen S, Michaud GF.

J Cardiovasc Electrophysiol. 2011 Mar;22(3):248-54. doi: 10.1111/j.1540-8167.2010.01894.x. Epub 2010 Aug 31.

PMID:
20812929
3.

Safety of ablation for atrial fibrillation with therapeutic INR: comparison with transition to low-molecular-weight heparin.

Saad EB, Costa IP, Costa RE, Inácio LA Jr, Slater C, Camiletti A, Moura Neto DG, Maldonado P, Camanho LE, Polanczky CA.

Arq Bras Cardiol. 2011 Oct;97(4):289-96. Epub 2011 Aug 19. English, Portuguese.

4.

Influence of the concomitant use of heparin on the effects of warfarin during catheter ablation for atrial fibrillation.

Inada K, Matsuo S, Tokutake K, Yokoyama K, Hioki M, Narui R, Ito K, Tanigawa S, Yamashita S, Tokuda M, Shibayama K, Miyanaga S, Sugimoto K, Yoshimura M, Yamane T.

Heart Vessels. 2016 Mar;31(3):397-401. doi: 10.1007/s00380-014-0608-2. Epub 2014 Dec 4.

PMID:
25471944
5.

Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation.

Kwak JJ, Pak HN, Jang JK, Kim SK, Park JH, Choi JI, Hwang C, Kim YH.

J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):620-5. doi: 10.1111/j.1540-8167.2009.01670.x. Epub 2009 Dec 21.

PMID:
20039992
6.

Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio.

Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D, Verma A, Khaykin Y, Hongo R, Hao S, Beheiry S, Pelargonio G, Dello Russo A, Casella M, Santarelli P, Santangeli P, Wang P, Al-Ahmad A, Patel D, Themistoclakis S, Bonso A, Rossillo A, Corrado A, Raviele A, Cummings JE, Schweikert RA, Lewis WR, Natale A.

Circulation. 2010 Jun 15;121(23):2550-6. doi: 10.1161/CIRCULATIONAHA.109.921320. Epub 2010 Jun 1.

7.

Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.

Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C, Schweikert RA, Natale A.

Circulation. 2014 Jun 24;129(25):2638-44. doi: 10.1161/CIRCULATIONAHA.113.006426. Epub 2014 Apr 17.

8.

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.

Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA.

Europace. 2014 Oct;16(10):1443-9. doi: 10.1093/europace/euu196. Epub 2014 Aug 12.

9.

Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.

Kuwahara T, Abe M, Yamaki M, Fujieda H, Abe Y, Hashimoto K, Ishiba M, Sakai H, Hishikari K, Takigawa M, Okubo K, Takagi K, Tanaka Y, Nakajima J, Takahashi A.

J Cardiovasc Electrophysiol. 2016 May;27(5):549-54. doi: 10.1111/jce.12928. Epub 2016 Feb 12.

PMID:
26766541
10.

Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration.

Kuwahara T, Takahashi A, Takahashi Y, Kobori A, Miyazaki S, Takei A, Fujino T, Okubo K, Takagi K, Fujii A, Takigawa M, Watari Y, Hikita H, Sato A, Aonuma K.

J Cardiovasc Electrophysiol. 2013 May;24(5):510-5. doi: 10.1111/jce.12069. Epub 2013 Jan 25.

PMID:
23350877
11.

Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin.

Shin DG, Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, Pak HN.

Yonsei Med J. 2016 Mar;57(2):342-9. doi: 10.3349/ymj.2016.57.2.342.

12.

The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin.

Kim JS, Jongnarangsin K, Latchamsetty R, Chugh A, Ghanbari H, Crawford T, Yokokawa M, Good E, Bogun F, Pelosi F Jr, Morady F, Oral H.

Circ Arrhythm Electrophysiol. 2013 Apr;6(2):302-9. doi: 10.1161/CIRCEP.112.000143. Epub 2013 Feb 26.

13.
14.

Periprocedural anticoagulation of patients undergoing pericardiocentesis for cardiac tamponade complicating catheter ablation of atrial fibrillation.

Lin T, Bai R, Chen YW, Yu RH, Tang RB, Sang CH, Li SN, Ma CS, Dong JZ.

Int Heart J. 2015;56(1):56-61. doi: 10.1536/ihj.14-158. Epub 2014 Dec 11.

16.

Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE, Garbati MA, Bahmaid RA, Wimmer AP.

Europace. 2013 Oct;15(10):1412-20. doi: 10.1093/europace/eut239. Epub 2013 Aug 16. Review.

PMID:
23954918
17.

Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.

Dentali F, Pignatelli P, Malato A, Poli D, Di Minno MN, Di Gennaro L, Rancan E, Pastori D, Grifoni E, Squizzato A, Siragusa S, Di Minno G, Ageno W.

Am J Hematol. 2012 Apr;87(4):384-7. doi: 10.1002/ajh.23119. Epub 2012 Feb 24. Erratum in: Am J Hematol. 2012 Jul;87(7):748. Grifoni, Elena [corrected to Grifoni, Elisa].

18.

Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.

Takarada K, Sato M, Goto M, Saito A, Ikeda Y, Fujita S, Fuse K, Takahashi M, Oguro T, Matsushita H, Kitazawa H, Okabe M, Abe H, Toba K, Yamashina A, Aizawa Y.

J Cardiol. 2014 Aug;64(2):127-32. doi: 10.1016/j.jjcc.2013.11.015. Epub 2014 Jan 17.

19.

Periprocedural anticoagulation for atrial fibrillation ablation.

Mortada ME, Chandrasekaran K, Nangia V, Dhala A, Blanck Z, Cooley R, Bhatia A, Gilbert C, Akhtar M, Sra J.

J Cardiovasc Electrophysiol. 2008 Apr;19(4):362-6. doi: 10.1111/j.1540-8167.2007.01071.x. Epub 2008 Feb 12.

PMID:
18284509
20.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933

Supplemental Content

Support Center